Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced HCC Who Were Sorafenib Intolerant or Refractory
5-year results from the CheckMate 040 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
5-year results from the CheckMate 040 study
Findings from the RADICALS-HD study
Evidence for efficacy is based on the results from the DeLLphi-301 study
Updated analysis of the phase II NeoCombi study
New indication concerns adjuvant treatment for ALK-positive NSCLC at high risk of recurrence
Findings from the CheckMate 77T study
Findings from the exploratory biomarker analyses of the DESTINY-Gastric01 study
Findings from the FIGHT-207 basket study
It is indicated in combination with cisplatin and gemcitabine
Primary results from the DESTINY-PanTumor01 study
Approval is based on pharmacokinetic, dosimetry, and safety data from NETTER-P study in adolescent patients and also on the extrapolation of efficacy outcomes observed in NETTER-1 study which supported the original approval in adult patients
Findings from the TRIANGLE study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
Analytics cookies help us improve our website by collecting and reporting information on its usage.
We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.